Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENXBIO Inc.RGNX · Entity 2211 | Chief Financial Officer | March 19, 2024 | March 21, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENXBIO Inc.
Report date March 19, 2024 · Filed March 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 246,534 |
Reported balance
After 2024-03-19 transaction · row 1
1 source rowRow 1 · 2024-03-19 · Exercise / conversion · Acquired 20,041 · Balance 246,534 |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.76 · Expires 2025-05-19 | Direct | 0 |
Reported balance
After 2024-03-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-03-19 · Exercise / conversion · Disposed 20,041 · Balance 0 F1: The previously granted option, representing a right to purchase a total of 30,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The previously granted option, representing a right to purchase a total of 30,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2020 Filed Apr 2, 2020 16:22 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001562180-20-002850 · primarydocument.xml · derivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,900 Underlying: Common Stock · 10,000 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 424,900 shares, became exercisable as follows: 284,683 of the shares subject to the option are initial shares ("Initial Shares") and 140,217 of the shares subject to the option are contingent shares ("Contingent Shares"). 72,235 of the Initial Shares vested on September 17, 2014, 53,112 of the Initial Shares vested on September 17, 2015 and an additional 4,426 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter. F2 · derivative.exercise_date: (Continued from footnote 1) Notwithstanding the foregoing, 59,533 shares subject to this option that would otherwise have vested monthly between January 2018 and September 2018 were deemed vested as of December 31, 2015 on January 28, 2016 due to subsequent events. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 16:22 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 10,000 | $0.85 | $8,500.00 |
DisclosureSEC source: 0001562180-20-002850 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,215 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 16:24 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $13.09 | $0.00 |
DisclosureSEC source: 0001562180-20-001111 · primarydocument.xml · derivative · entry 4 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,374 Underlying: Common Stock · 3,000 shares Expires 2026-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 75,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 28, 2017, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 16:24 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 14,129 | $50.12 | $708,145.48 |
DisclosureSEC source: 0001562180-20-001111 · primarydocument.xml · nonDerivative · entry 3 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,215 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $49.74 to $50.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 16:24 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 677 | $49.05 | $33,206.85 |
DisclosureSEC source: 0001562180-20-001111 · primarydocument.xml · nonDerivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,344 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $48.64 to $49.47. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 16:24 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 3,000 | $13.09 | $39,270.00 |
DisclosureSEC source: 0001562180-20-001111 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,021 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 16:21 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 300 | $50.00 | $15,000.00 |
DisclosureSEC source: 0001562180-20-001014 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,021 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 17, 2020 Filed Jan 21, 2020 16:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 2,394 | $50.00 | $119,700.00 |
DisclosureSEC source: 0001562180-20-000453 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,321 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $50.00 to $50.02. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 16:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $13.09 | $0.00 |
DisclosureSEC source: 0001562180-20-000321 · primarydocument.xml · derivative · entry 4 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,374 Underlying: Common Stock · 3,000 shares Expires 2026-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 75,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 28, 2017, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 16:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 5,100 | $41.92 | $213,792.00 |
DisclosureSEC source: 0001562180-20-000321 · primarydocument.xml · nonDerivative · entry 3 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,715 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $41.70 to $42.19. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 16:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 2,400 | $41.40 | $99,360.00 |
DisclosureSEC source: 0001562180-20-000321 · primarydocument.xml · nonDerivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,815 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $40.66 to $41.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 16:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 3,000 | $13.09 | $39,270.00 |
DisclosureSEC source: 0001562180-20-000321 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,215 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 16:21 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $38.99 | $0.00 |
DisclosureSEC source: 0001562180-20-000216 · primarydocument.xml · derivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-01-02 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 2, 2021 while the optionee provides continuous service to the Issuer. Read SEC document |
| March 21, 2019 Filed Mar 25, 2019 12:32 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 1,700 | $61.31 | $104,227.00 |
DisclosureSEC source: 0001562180-19-002018 · primarydocument.xml · nonDerivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,215 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $61.12 to $61.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 21, 2019 Filed Mar 25, 2019 12:32 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 8,300 | $60.64 | $503,312.00 |
DisclosureSEC source: 0001562180-19-002018 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,915 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $60.12 to $61.09. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 16:23 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 3,068 | $60.01 | $184,110.68 |
DisclosureSEC source: 0001562180-19-001801 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,215 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $60.00 to $60.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 07, 2019 Filed Feb 11, 2019 16:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001562180-19-000874 · primarydocument.xml · derivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,900 Underlying: Common Stock · 120,000 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 424,900 shares, became exercisable as follows: 284,683 of the shares subject to the option are initial shares ("Initial Shares") and 140,217 of the shares subject to the option are contingent shares ("Contingent Shares"). 72,235 of the Initial Shares vested on September 17, 2014, 53,112 of the Initial Shares vested on September 17, 2015 and an additional 4,426 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter. F2 · derivative.exercise_date: (Continued from footnote 1) Notwithstanding the foregoing, 59,533 shares subject to this option that would otherwise have vested monthly between January 2018 and September 2018 were deemed vested as of December 31, 2015 on January 28, 2016 due to subsequent events. Read SEC document |
| February 07, 2019 Filed Feb 11, 2019 16:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 120,000 | $0.85 | $102,000.00 |
DisclosureSEC source: 0001562180-19-000874 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,283 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 16:23 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 57,000 | $0.00 Strike: $40.82 | $0.00 |
DisclosureSEC source: 0001562180-19-000219 · primarydocument.xml · derivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,000 Underlying: Common Stock · 57,000 shares Expires 2029-01-03 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 3, 2020 while the optionee provides continuous service to the Issuer. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 16:32 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 1,700 | $47.74 | $81,158.00 |
DisclosureSEC source: 0001562180-18-005051 · primarydocument.xml · nonDerivative · entry 3 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,283 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $47.38 to $48.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 16:32 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 1,700 | $46.47 | $78,999.00 |
DisclosureSEC source: 0001562180-18-005051 · primarydocument.xml · nonDerivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,983 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $46.21 to $47.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 16:32 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 4,100 | $45.73 | $187,493.00 |
DisclosureSEC source: 0001562180-18-005051 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,683 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $45.21 to $46.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 16:16 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 100 | $64.10 | $6,410.00 |
DisclosureSEC source: 0001562180-18-004611 · primarydocument.xml · nonDerivative · entry 6 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,783 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 16:16 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 700 | $63.05 | $44,135.00 |
DisclosureSEC source: 0001562180-18-004611 · primarydocument.xml · nonDerivative · entry 5 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,883 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $62.81 to $63.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 16:16 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 2,042 | $62.23 | $127,073.66 |
DisclosureSEC source: 0001562180-18-004611 · primarydocument.xml · nonDerivative · entry 4 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,583 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $61.81 to $62.74. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 16:16 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 588 | $60.40 | $35,515.20 |
DisclosureSEC source: 0001562180-18-004611 · primarydocument.xml · nonDerivative · entry 3 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,625 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $59.98 to $60.69. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 16:16 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 1,900 | $59.06 | $112,214.00 |
DisclosureSEC source: 0001562180-18-004611 · primarydocument.xml · nonDerivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,213 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $58.81 to $59.77. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 16:16 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 2,170 | $58.46 | $126,858.20 |
DisclosureSEC source: 0001562180-18-004611 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,113 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $57.68 to $58.66. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 02, 2018 Filed Nov 5, 2018 16:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 20,833 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0001562180-18-004417 · primarydocument.xml · derivative · entry 10 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,167 Underlying: Common Stock · 20,833 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F6 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 50,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 4, 2018, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| November 02, 2018 Filed Nov 5, 2018 16:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 32,908 | $0.00 Strike: $13.09 | $0.00 |
DisclosureSEC source: 0001562180-18-004417 · primarydocument.xml · derivative · entry 9 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,374 Underlying: Common Stock · 32,908 shares Expires 2026-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F5 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 75,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 28, 2017, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| November 02, 2018 Filed Nov 5, 2018 16:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 53,741 | $70.26 | $3,775,842.66 |
DisclosureSEC source: 0001562180-18-004417 · primarydocument.xml · nonDerivative · entry 6 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,283 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $70.00 to $70.74. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 02, 2018 Filed Nov 5, 2018 16:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 20,833 | $19.50 | $406,243.50 |
DisclosureSEC source: 0001562180-18-004417 · primarydocument.xml · nonDerivative · entry 5 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 02, 2018 Filed Nov 5, 2018 16:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 32,908 | $13.09 | $430,765.72 |
DisclosureSEC source: 0001562180-18-004417 · primarydocument.xml · nonDerivative · entry 4 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,191 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 16:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 9,718 | $0.00 Strike: $13.09 | $0.00 |
DisclosureSEC source: 0001562180-18-004417 · primarydocument.xml · derivative · entry 8 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,282 Underlying: Common Stock · 9,718 shares Expires 2026-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F5 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 75,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 28, 2017, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 16:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 9,959 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001562180-18-004417 · primarydocument.xml · derivative · entry 7 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,041 Underlying: Common Stock · 9,959 shares Expires 2025-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 30,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 16:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 19,677 | $70.04 | $1,378,177.08 |
DisclosureSEC source: 0001562180-18-004417 · primarydocument.xml · nonDerivative · entry 3 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,283 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $70.00 to $70.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 16:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 9,718 | $13.09 | $127,208.62 |
DisclosureSEC source: 0001562180-18-004417 · primarydocument.xml · nonDerivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,960 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 16:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 9,959 | $3.76 | $37,445.84 |
DisclosureSEC source: 0001562180-18-004417 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,242 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 16:24 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 5,000 | $59.59 | $297,950.00 |
DisclosureSEC source: 0001562180-18-004241 · primarydocument.xml · nonDerivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,283 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $59.34 to $59.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 16:24 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 2,500 | $58.93 | $147,325.00 |
DisclosureSEC source: 0001562180-18-004241 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,283 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $58.29 to $59.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 16:26 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001562180-18-003984 · primarydocument.xml · derivative · entry 12 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,900 Underlying: Common Stock · 30,000 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 424,900 shares, became exercisable as follows: 284,683 of the shares subject to the option are initial shares ("Initial Shares") and 140,217 of the shares subject to the option are contingent shares ("Contingent Shares"). 72,235 of the Initial Shares vested on September 17, 2014, 53,112 of the Initial Shares vested on September 17, 2015 and an additional 4,426 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter. F12 · derivative.exercise_date: (Continued from footnote 11) Notwithstanding the foregoing, 59,533 shares subject to this option that would have otherwise vested monthly between January 2018 and September 2018 were deemed vested as of December 31, 2015 on January 28, 2016 due to subsequent events. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 16:26 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 30,000 | $0.85 | $25,500.00 |
DisclosureSEC source: 0001562180-18-003984 · primarydocument.xml · nonDerivative · entry 11 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,783 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 16:26 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 100 | $80.80 | $8,080.00 |
DisclosureSEC source: 0001562180-18-003984 · primarydocument.xml · nonDerivative · entry 10 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,783 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 16:26 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 500 | $79.63 | $39,815.00 |
DisclosureSEC source: 0001562180-18-003984 · primarydocument.xml · nonDerivative · entry 9 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,883 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F10 · price: This transaction was executed in multiple trades at prices ranging from $79.40 to $80.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 16:26 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 450 | $78.64 | $35,388.00 |
DisclosureSEC source: 0001562180-18-003984 · primarydocument.xml · nonDerivative · entry 8 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,383 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F9 · price: This transaction was executed in multiple trades at prices ranging from $78.40 to $78.95. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 16:26 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 600 | $77.87 | $46,722.00 |
DisclosureSEC source: 0001562180-18-003984 · primarydocument.xml · nonDerivative · entry 7 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,833 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $77.40 to $78.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 16:26 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 1,479 | $76.79 | $113,572.41 |
DisclosureSEC source: 0001562180-18-003984 · primarydocument.xml · nonDerivative · entry 6 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,433 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $76.35 to $77.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 16:26 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 700 | $75.59 | $52,913.00 |
DisclosureSEC source: 0001562180-18-003984 · primarydocument.xml · nonDerivative · entry 5 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,912 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $75.00 to $75.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 16:26 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 710 | $74.02 | $52,554.20 |
DisclosureSEC source: 0001562180-18-003984 · primarydocument.xml · nonDerivative · entry 4 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,612 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $73.85 to $74.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 16:26 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 1,200 | $73.40 | $88,080.00 |
DisclosureSEC source: 0001562180-18-003984 · primarydocument.xml · nonDerivative · entry 3 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,322 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $72.80 to $73.75. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.